Insilico Medicine is set to present its advancements in AI-driven drug discovery at the upcoming BIO 2026 International Convention in San Diego, scheduled for June 22-25. The company aims to engage with biopharma partners and researchers, showcasing its Pharma.AI platform alongside its R&D pipeline.
Dr. Alex Zhavoronkov, the company's founder and CEO, will deliver four significant presentations during the event. These will cover a range of topics, including the impact of AI on drug development, innovations from China in the biopharma landscape, and the integration of quantum computing in drug discovery. The sessions are designed to highlight how Insilico Medicine is leveraging technology to enhance drug development processes.
The BIO International Convention is recognized as the largest biotechnology event globally, attracting around 20,000 industry professionals. It serves as a critical platform for collaboration, focusing on emerging trends in AI, digital health, and innovative therapies, among other topics. The event's BIO Partnering™ system facilitates technology transfers and licensing deals, further emphasizing its role in the biopharma industry.
Additionally, Dr. Frank Pun from Insilico Medicine will participate in the Global Women's Health Capital & Industry Summit in Shanghai, where he will discuss AI-driven solutions for unmet needs in women's health. This reflects Insilico's commitment to addressing significant healthcare challenges through advanced technology and strategic partnerships.